Phase
Condition
Inflammation
Scleroderma
Osteoporosis
Treatment
N/AClinical Study ID
Ages 60-80 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Ambulatory general population
Dietary intake of vitamin K below 120 mcg
Exclusion
Exclusion Criteria:
Unable to give informed consent
Usual dietary intake of phylloquinone greater than 120 µg/d
Usual dietary calcium intake greater than 1500 mg/d
Usual dietary vitamin D intake greater than 1500 IU
Women less than 5 years postmenopausal
Femoral neck BMD (bone mineral density) at screening that is greater than 1.8 SD aboveor below an age-matched reference mean
24-hour calcium to creatinine ratio exceeding 300 mg/g for women or 350 mg/g for men
Terminal illness
Renal or liver disease requiring treatment
Kidney stone in the past 5 years
Current hyperparathyroidism
Bilateral hip surgery
Treatment with a bisphosphonate, calcitonin, estrogen progestin, androgen, tamoxifen,or fluoride (other than dental rinse), or any other treatment for osteoporosis inprevious 3 months
Warfarin or anticoagulant use in the past 12 months
Nonambulation
Known coronary disease, defined by myocardial infarction or unstable angina
Prior open heart surgery
Atrial fibrillation
Study Design
Study Description
Connect with a study center
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
Boston, Massachusetts 02111
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.